Navigation Links
arGEN-X Presents Significant Progress at BioPharm America 2011
Date:9/7/2011

nsforming the therapeutic antibody space. The speed and productivity of our first three internal programs have enabled us to begin discovery work on two new therapeutic targets. These developments have been instrumental in attracting companies seeking a reliable, robust platform for generation of therapeutic grade antibody candidates. Given this progress, I am excited about arGEN-X' prospects for the coming year."

Note for the editor

About arGEN-X - http://www.arGEN-X.com

arGEN-X is a preclinical stage biopharmaceutical company with a broadly applicable, proprietary SIMPLE Antibody™ platform. The platform allows arGEN-X to create an unparalleled diversity of in vivo generated antibody leads against a broad range of human disease targets. This superior choice of ultra-high affinity and highly potent leads, having best-in-class human homology, allows for more stringent lead selection criteria, thereby increasing the probability of success later in the drug development path. The Company has validated its platform on four human disease targets to date and has broad patent claims in place covering its technology.

arGEN-X' SIMPLE Antibody™ Platform is based on the active immunisation of Camelids with target antigens to deliver antibody variable regions that are perfectly matched to those of human antibodies. The combination of those variable domains with the constant domains of human antibodies, generates full size, human therapeutic antibodies.

The SIMPLE Antibody™ Platform enjoys an independent, unencumbered patent position and is free of target gatekeeping restrictions.

arGEN-X™ and SIMPLE Antibody™ are deposited trademarks of arGEN-X BV.

SIMPLE stands for Superior Immunodiversity with Minimal Protein Lead Engineering.

For further information, please contact:


  
'/>"/>

SOURCE arGEN-X
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. arGEN-X Announces Non-Exclusive License With BioWa for POTELLIGENT® Technology
2. arGEN-X Granted Broad Patent Covering its Unique SIMPLE Antibody(TM) Platform
3. arGEN-X SIMPLE Antibody(TM) Platform set to Transform Therapeutic Antibody Discovery & Development
4. arGEN-X Concludes EUR 12.5 Million Series A Financing Round
5. Elan Pharmaceuticals Presents 7th Annual Danville Concours dElegance Weekend
6. Codexis Presents Carbon Capture Update at DoE/NETL Conference
7. Cardium Presents Second Quarter 2011 Financial Results and Reports on Near-Term Milestones
8. Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimers Disease Research
9. Amerigroup Foundation Presents Grant to Rx Partnership
10. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
11. Prime Therapeutics Vice President of Specialty Pharmacy Solutions Presents at 6th Annual Executive Forum on Pharmacy Benefit Management Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... N.C. , Aug. 1, 2014  With monumental ... learning to speak a second language. Clinical efficacy is ... agencies established under the ACA like PCORI are directing ... a variety of new entities and environments, the federal ... speak the new language of outcomes and managed markets ...
(Date:8/1/2014)... WASHINGTON , Aug. 1, 2014 In ... of treatments for sexual dysfunction, more than 60 doctors ... penned an open letter questioning the Food and Drug ... the most common form of male sexual dysfunction compared ... on the agency to act for women by approving ...
(Date:8/1/2014)... According to the new ... Anti infective), Basic (Films, Cleansing), Advanced (Hydrogels, Hydrocolloids, ... Pressure Relief Devices, NPWT) - Global Forecast to ... is expected to reach $18.3 Billion by 2019 ... CAGR of 3.2% from 2014 to 2019. ...
Breaking Medicine Technology:Pharmaceuticals Learning the Language of the New Healthcare Landscape 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 360+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 3Wound Care Market Worth $18.3 Billion by 2019 2Wound Care Market Worth $18.3 Billion by 2019 3
... Banner Health and ... jointly announce Banner Health,s system-wide conversion to Masimo rainbow® SET ... Health hospital will be cared for using the most technologically ... "The decision to convert our entire hospital system ...
... 2, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Medicine Technology:Banner Health Converts 23-Hospital System to Masimo rainbow SET Technology 2Banner Health Converts 23-Hospital System to Masimo rainbow SET Technology 3Banner Health Converts 23-Hospital System to Masimo rainbow SET Technology 4Banner Health Converts 23-Hospital System to Masimo rainbow SET Technology 5Banner Health Converts 23-Hospital System to Masimo rainbow SET Technology 6Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 2Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 3Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 4Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 5Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 6Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 7Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 8
(Date:8/1/2014)... plays a central role in regulating appetite and whole-body ... the brain,s control of food intake and body weight, ... has been unclear. A new study in ... PPARγ activity in a type of neuron known as ... to high-fat diet. Sabrina Diano and colleagues at ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Stryker ... wake of the 2012 Rejuvenate and ABG II ... in New Jersey’s Bergen County Superior Court, Bernstein ... the proceeding, the Court has issued a ... any and all hard copy and electronic materials ...
(Date:8/1/2014)... at University Hospitals Rainbow Babies & Children,s Hospital (UH ... risk for death on a commercial airline flight. The ... January 2010 and June 2013 and found 90 percent ... 2. , The study was conducted in partnership ... in-flight pediatric fatality onboard commercial airline flights worldwide. Through ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 The ... for independent community pharmacies. At ThoughtSpot 2014, AmerisourceBergen ... equipped with practices and resources to enhance patient ... leaders focused on critical issues to give independent ... and grow. , ThoughtSpot show attendance experienced ...
(Date:8/1/2014)... of a cancer diagnosis may improve health outcomes for ... by a researcher at the University of Houston (UH). ... intervention is the writing instruction. Otherwise, writing is just ... journal can be therapeutic, but oftentimes we don,t get ... not," said Qian Lu, assistant professor and director of ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:New research characterizes in-flight pediatric deaths 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3
... Blood donors with hemochromatosis, a disorder in which iron ... a greater risk to blood safety than other donors, ... the National Heart, Lung, and Blood Institute (NHLBI). // ... or "blood letting" to remove excess iron from their ...
... Researchers at Harvard Medical School have looked at the use ... They find that the use of 20 therapies - from ... 1960s. A new survey reveals that complementary and alternative medicine ... has changed over the years. // ...
... heart disease can expect to live longer if they take ... for people with a high risk of stroke or heart ... - preventing clotting - and also reduces inflammation. A new ... US now reveals that aspirin reduces deaths from all causes ...
... found a cheap and non toxic method of treating Hepatitis, ... virus infects the liver, and in severe cases can lead ... through contact with the blood or body fluids of an ... HBV after a very bright and aware patient observed that ...
... heal wounds made inside the body during surgery without scarring. ... stops tissues sticking together to form painful scars. One of ... be used ,during keyhole surgery, which is now commonly preferred ... made from polyethylene glycol, is now undergoing clinical trials in ...
... relief for chronic pain, and should be studied for ... conference in Glasgow.,Dr William Notcutt of the James Paget ... used in his study - applied as a spray ... chronic pain. He announced the findings at the annual ...
Cached Medicine News:
Microalbumin Linearity Control...
Total IgE Control...
The K-ASSAY Lipid Controls are assayed controls produced from fresh human sera to monitor the accuracy and precision of quantitative lipid determinations of human sera specimens....
The K-ASSAY hs-CRP Control Set is intended to be used as a consistent test sample of known concentrations for monitoring the performance of hs-CRP (high sensitive C-Reactive Protein) immunoturbimetri...
Medicine Products: